Allergy Therapeutics Plc (AGY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Allergy Therapeutics Plc (AGY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12394
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alternative of aluminium to develop aluminium-free immunotherapy vaccines. Allergy Therapeutics product portfolio includes Pollinex Grasses + Rye and Pollinex Trees vaccines. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, Slovakia, Czech Republic, the Netherlands and the UK. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Allergy Therapeutics Plc (AGY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 11
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12
Equity Offering 13
Allergy Therapeutics Raises USD13.9 Million in Public Offering of Shares 13
Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 15
Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 16
Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 18
Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 19
Allergy Therapeutics Completes Private Placement Of Shares For US$0.3 Million 21
Acquisition 23
Allergy Therapeutics Acquires Alerpharma 23
Allergy Therapeutics Plc – Key Competitors 24
Allergy Therapeutics Plc – Key Employees 25
Allergy Therapeutics Plc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 28
Financial Announcements 28
Sep 26, 2018: Allergy Therapeutics announces preliminary results for the year ended 30 June 2018 28
Jul 12, 2018: Allergy Therapeutics: Trading Update 33
Mar 07, 2018: Allergy Therapeutics: Interim Results for the six months ended 31 December 2017 34
Sep 28, 2017: Allergy Therapeutics: Preliminary Results 37
Mar 29, 2017: Allergy Therapeutics: Interim Results for the six months ended 31 December 2016 42
Jan 19, 2017: Allergy Therapeutics Provides Trading Update 43
Corporate Communications 44
Nov 08, 2018: Allergy Therapeutics: Director change 44
Jun 06, 2017: Allergy Therapeutics: Directorate changes 45
Feb 08, 2017: Allergy Therapeutics: Directorate Change 46
Product News 47
06/25/2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 47
05/29/2018: Allergy Therapeutics – Positive new data with house-dust mite immunotherapy 48
May 14, 2018: Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®), in The Journal of Immunology 49
02/28/2018: Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac Peanut allergy product 50
Clinical Trials 51
May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study 51
Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial 52
Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment 53
Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial 54
Sep 18, 2017: Allergy Therapeutics: Approval of clinical trial application for PQ Grass Phase II trial 55
Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study 56
Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 57
Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine 58
Other Significant Developments 59
Feb 02, 2018: Allergy Therapeutics Announces Corporate Update 59
Jan 31, 2018: Allergy Therapeutics: Trading Update 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Allergy Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 11
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12
Allergy Therapeutics Raises USD13.9 Million in Public Offering of Shares 13
Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 15
Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 16
Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 18
Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 19
Allergy Therapeutics Completes Private Placement Of Shares For US$0.3 Million 21
Allergy Therapeutics Acquires Alerpharma 23
Allergy Therapeutics Plc, Key Competitors 24
Allergy Therapeutics Plc, Key Employees 25
Allergy Therapeutics Plc, Subsidiaries 26

List of Figures
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Allergy Therapeutics Plc (AGY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務分析
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • China Digital Culture (Group) Limited (8175):企業の財務・戦略的SWOT分析
    China Digital Culture (Group) Limited (8175) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • GVK Power and Infrastructure Ltd (GVKPIL):電力:M&Aディール及び事業提携情報
    Summary GVK Power and Infrastructure Ltd (GVKPIL), formerly Jegurupadu Operation & Maintenance Company Limited, is a diversified infrastructure company that operates across various sectors including energy, transportation, hospitality, resources, airports, and life sciences. It carries out construct …
  • WIV Wein International AG:企業の戦略・SWOT・財務情報
    WIV Wein International AG - Strategy, SWOT and Corporate Finance Report Summary WIV Wein International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Comtek Advanced Structures Ltd.:企業の戦略・SWOT・財務情報
    Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report Summary Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Croatia Airlines dd:戦略・SWOT・企業財務分析
    Croatia Airlines dd - Strategy, SWOT and Corporate Finance Report Summary Croatia Airlines dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Montefiore Medical Center-医療機器分野:企業M&A・提携分析
    Summary Montefiore Medical Center (MMC) is a healthcare service provider that offers clinical services. The center offers services such as allergy and immunology, orthopaedics, dentistry and oral surgery, dermatology, endocrinology, digestive and liver diseases, neurological surgery, otorhinolaryngo …
  • Taylor-DeJongh Inc:企業の戦略・SWOT・財務情報
    Taylor-DeJongh Inc - Strategy, SWOT and Corporate Finance Report Summary Taylor-DeJongh Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Elmet Technologies Inc:企業の戦略・SWOT・財務分析
    Elmet Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary Elmet Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Generali Brasil Seguros S.A.:企業の戦略・SWOT・財務情報
    Generali Brasil Seguros S.A. - Strategy, SWOT and Corporate Finance Report Summary Generali Brasil Seguros S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Viztek LLC-医療機器分野:企業M&A・提携分析
    Summary Viztek LLC (Viztek), a subsidiary of Konica Minolta Medical Imaging USA Inc is a healthcare technology company that offers digital software and hardware imaging solutions. The company offers products such as opal-ORTHO, Opal-wRIS, CR, opal-CR II, opal-CHIRO, opal-RAD, opal-CLOUD, Viztek DR, …
  • Sorrento Therapeutics, Inc.:企業のM&A・事業提携・投資動向
    Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sorrento Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • LIncoln Electric Holdings Inc:企業の戦略・SWOT・財務情報
    LIncoln Electric Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary LIncoln Electric Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • TransMontaigne Partners LP (TLP):企業の財務・戦略的SWOT分析
    Summary TransMontaigne Partners LP (TLP), a subsidiary of TransMontaigne GP LLC is an energy infrastructure service provider that offers integrated terminaling, transportation, and storage services. The company distributes and transports crude oil, chemicals, petroleum products, fertilizers, and oth …
  • LifeScan Inc:企業の戦略的SWOT分析
    LifeScan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Fintel Energia Group SpA (FTL):企業の財務・戦略的SWOT分析
    Summary Fintel Energia Group SpA (Fintel) is a utility service provider that supplies electricity and natural gas. The company's services include designing, consultation, and installation of technologies and system of production of renewable energies for the Group and to third parties. It also provi …
  • ICICI Lombard General Insurance Company Limited:企業の戦略・SWOT・財務情報
    ICICI Lombard General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary ICICI Lombard General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Tohoku Electric Power Company, Incorporated:企業の戦略・SWOT・財務情報
    Tohoku Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Tohoku Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Affimed GmbH (AFMD):企業の財務・戦略的SWOT分析
    Summary Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, discovers and develops immunotherapies to treat hematologic cancers and solid tumors. The company is investigating AFM13, an innate cell engager, for the treatment of Peripheral T cell lymphoma, transformed …
  • Four Seasons Hotels Ltd:企業の戦略・SWOT・財務情報
    Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆